- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Pharmala Biotech Holdings Inc: Pharmala completes shipment of LaNeo MDMA to Yale | 2 | Stockwatch | ||
| Di | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to Yale University, Provides Investor Update | 1 | GlobeNewswire (USA) | ||
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| Fr | Pharmala Biotech Holdings Inc: Pharmala sniffs out counterfeit nasal spray on-line | 2 | Stockwatch | ||
| Fr | PharmAla warns against fake MDMA products bearing its name | 1 | The Market Herald Canada | ||
| Fr | PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla | 139 | GlobeNewswire (Europe) | TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing... ► Artikel lesen | |
| 15.05. | PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines | 3 | GlobeNewswire (USA) | ||
| 30.04. | PharmAla Biotech: PharmAla Issues Q2 Financial Statements | 1.098 | GlobeNewswire (Europe) | TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 24.03. | Pharmala Biotech Holdings Inc: Pharmala contracts third party logistics outfit in U.S. | 3 | Stockwatch | ||
| 24.03. | PharmAla Biotech: PharmAla Contracts with Partner to Act as US Distributor | 3 | GlobeNewswire (USA) | ||
| 21.03. | Pharmala Biotech Holdings Inc: Pharmala ships LaNeo MDMA to University of Washington | 3 | Stockwatch | ||
| 21.03. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to the University of Washington | 2 | GlobeNewswire (USA) | ||
| 10.03. | Pharmala Biotech Holdings Inc: Pharmala enters Dutch distribution deal with Duchefa | 1 | Stockwatch | ||
| 10.03. | PharmAla Biotech: PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands | 250 | GlobeNewswire (Europe) | TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 04.03. | Pharmala Biotech Holdings Inc: Pharmala completes shipment of LaNeo MDMA to UCLA | 1 | Stockwatch | ||
| 03.03. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to UCLA for Schizophrenia Study | 1 | GlobeNewswire (USA) | ||
| 28.02. | Pharmala Biotech Holdings Inc: Pharmala's UT Health contract to move forward | 3 | Stockwatch | ||
| 27.02. | PharmAla Biotech: PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 07.02. | Pharmala Biotech Holdings Inc: Pharmala Biotech hires Azrieli for advisory services | 2 | Stockwatch | ||
| 06.02. | PharmAla Biotech: PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli | 1 | GlobeNewswire (USA) | ||
| 30.01. | Pharmala Biotech Holdings Inc: Pharmala talks revenue slowdown; NR omits Q1 P&L | 1 | Stockwatch |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| BIONTECH | 99,40 | +1,95 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
| DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
| QIAGEN | 40,440 | +0,29 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,330 | -0,64 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| 89BIO | 10,050 | 0,00 % | 89bio hält Jahreshauptversammlung ab, Direktoren gewählt | ||
| ARCUTIS BIOTHERAPEUTICS | 13,260 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung und 19 US-Dollar Kursziel für Arcutis-Aktie | ||
| KYMERA THERAPEUTICS | 44,310 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
| EVOTEC | 7,152 | +0,11 % | Evotec, GFT Technologies, InflaRx, Nordex, Rheinmetall, ThyssenKrupp - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen |
Das Unternehmen PHARMALA BIOTECH HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.